We report a case of pemphigus foliaceous (PF) in the setting of bamlanivimab, a novel monoclonal antibody for the treatment of COVID-19. PF is a rare autoimmune blistering disease caused by autoantibodies directed against desmoglein-1 (DSG1). Drugs and viruses have been implicated as inciting factors of pemphigus in predisposed patients. Given the current pandemic, the presentation of PF following COVID-19 infection and bamlanivimab infusion is of special interest and further investigation may be warranted.